

2019 PD THERAPEUTICS CONFERENCE

The Michael J. Fox Foundation for Parkinson's Research 13th Annual Parkinson's Disease Therapeutics Conference

October 15, 2019

New York, NY

POSTER SESSION

MICHAEL SCHWARZSCHILD, PhD, MD

Massachusetts General Hospital

Results from the SURE-PD3 Trial - Title TBD

ROGER ALBIN, MD

University of Michigan

"Alpha4Beta2 Nicotinic Agonist for Treatment of L-Dopa Refractory Gait and Balance Disorders in Parkinson Disease"

ROSA CANET-AVILES, PhD

Foundation for the National Institutes of Health (FNIH)

"AMP PD: Collaborating in the discovery of biomarkers to accelerate the development of therapies for Parkinson's Disease"

MATTHEW HAVRDA, PhD

Geisel School of Medicine at Dartmouth

"Plasma-borne pyroptosis-related protein NLRP3 associated with Parkinson's disease"

LORRAINE IACOVITTI, PhD

Thomas Jefferson University

"Validating Astrocyte-Produced Protein GDF15 as a Novel Neuroprotective Therapy"

HEATHER LASSETER, PhD

Cohen Veterans Biosciences

"RAPID-Dx Inflammatory Biomarkers Platform Comparison Study"

DINA KATABI, PhD

Massachusetts Institute of Technology

"Observational Study of Emerald Related to Mobility in Parkinson's Patients"

INGA PETER, PhD

Ichan School of Medicine at Mount Sinai

"Genetic, Clinical, and Therapeutic Links between Crohn's Disease and Parkinson's Disease"

MARCUS UNGER, MD

Saarland University

"The Effect of Resistant Starch on Bowel Habits, Short Chain Fatty Acids and Gut Microbiota in Parkinson's Disease - The RESISTA-PD trial"

ERIK STOOPS, PhD

ADx Neurosciences

"Optimized standard operating procedures for analysis of α -synuclein in biological fluids (CSF, plasma): a data-driven approach"

FEI WANG, PhD

Weil Cornell Medicine

"Subtyping Parkinson's Disease with Multi-modal Data"

SAKURA MINAMI, PhD

Alkahest, Inc.

"AKST4290"

